Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
116,964,738
-
Total 13F shares
-
86,685,207
-
Share change
-
+8,699,408
-
Total reported value
-
$370,290,994
-
Put/Call ratio
-
137%
-
Price per share
-
$4.27
-
Number of holders
-
159
-
Value change
-
+$30,644,927
-
Number of buys
-
97
-
Number of sells
-
70
Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) as of Q2 2023
As of 30 Jun 2023,
Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS) was held by
159 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
86,685,207 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, Temasek Holdings (Private) Ltd, CITADEL ADVISORS LLC, JPMORGAN CHASE & CO, Kohlberg Kravis Roberts & Co. L.P., MORGAN STANLEY, STATE STREET CORP, Aristotle Capital Boston, LLC, and MARSHALL WACE, LLP.
This page lists
159
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.